Date	Article
15 July 2008	Oxford BioMedica Reports Further Data from Interim Review of TroVax® Phase III Trist Study
14 July 2008	Oxford BioMedica Receives Commitment For Independent Phase III Trial Of TroVax® In Adjuvant Colorectal Cancer
11 July 2008	Oxford BioMedica Announces Data Safety Monitoring Board Recommendation for TroVax® Phase III Trist Study
01 July 2008	Oxford BioMedica Response to Bavarian Nordic's US Litigation
01 July 2008	Oxford BioMedica Announces Update on Board Changes
24 June 2008	Oxford BioMedica to Present at Jefferies Healthcare Conference
02 June 2008	Sanofi-Aventis and Oxford BioMedica report encouraging TroVax® Phase II Trial results in metastatic renal cancer
27 May 2008	Oxford BioMedica to Present at FBR Capital Markets Spring Investor Conference
19 May 2008	Oxford BioMedica to Present at Rodman & Renshaw Healthcare Conference
16 May 2008	Oxford BioMedica Announces TroVax® Phase II Trial Results in Renal Cancer to be Presented at ASCO
09 May 2008	Oxford BioMedica Annual General Meeting
09 May 2008	Oxford BioMedica Interim Management Statement
21 April 2008	Notice of Annual General Meeting
15 April 2008	Oxford BioMedica Announces Board Changes
25 March 2008	Oxford BioMedica Report Encouraging New Phase II Trial Results with TroVax® in Prostate Cancer View abstract (14 kB)
17 March 2008	Oxford BioMedica to present at Cowen and Company Health Care Conference
10 March 2008	Oxford BioMedica Appoints Dr Alex Lewis as Non-Executive Director
10 March 2008	Oxford BioMedica Completes Patient Recruitment for Phase III TRIST study of TroVax® in Renal Cancer
10 March 2008	Oxford BioMedica Plc Preliminary Results for the Year Ended 31 December 2007
20 February 2008	Oxford BioMedica Announces Data Safety Monitoring Board Recommendation to Continue TroVax® Phase II Trist Study Achievement Triggers €10 Million Milestone Payment from Sanofi-Aventis
07 February 2008	Oxford BioMedica: Notice of FY2007 Preliminary Results
22 January 2008	Oxford BioMedica Announces Development Milestone in its Collaboration with MolMed
07 January 2008	Oxford BioMedica Secures Exclusive Licence to Key Intellectual Property for RNA Interference Gene Silencing Using LentiVector® Technology

Website by College Hill - Life Sciences